All In MedTech

Device Trial Radar · NCT05118997

Active Removal of IntraCerebral Hematoma Via Active Irrigation

Active Removal of IntraCerebral Hematoma Via Active Irrigation of the Ventricular System

Last checked: Nov 19, 2026Latest source record: Aug 1, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

60

Planned (sponsor's estimate)

Start

Oct 25, 2021

Primary completion

Jul 2025

Study completion Sep 2025

Sponsor

Lead sponsor
IRRASNot on our public-company list
Sponsor type
Industry
Collaborators
University of Helsinki; Northwestern University; West Virginia University; Klinikum Bergmannstrost; Stony Brook University; Icahn School of Medicine at Mount Sinai; Buffalo General Medical Center
First posted
Nov 12, 2021

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Factorial
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Study evaluating if active irrigation by IRRAflow® with infusion of tPA will reduce the time needed for clearance of intracerebral and intraventricular hemorrhage compared with passive drainage.

Conditions

  • Cerebral Hemorrhage
  • Intraventricular Hemorrhage

Interventions

  • IRRAflowDevice

    IRRAflow consists of a control unit and disposables (dual-lumen catheter and tube set) to offer an integrated and synchronized active fluid exchange system. Active fluid exchange is the combination of traditional gravity-driven drainage with periodic, controlled irrigation of the catheter probe to exchange any pathological fluid collection with neutral physiological fluids.

  • EVDDevice

    An external ventricular drain (EVD), also known as a ventriculostomy or extraventricular drain, is a device used in neurosurgery to treat hydrocephalus and relieve elevated intracranial pressure when the normal flow of cerebrospinal fluid inside the brain is obstructed.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Efficacy and safety of evacuation of intraventricular hematoma by Active External Ventricular Drainage (IRRAflow) with tPA administration compared to Passive External Ventricular Drainage (EVD) with tPA administration.Time frame: Intra-procedure
  2. Radiographic evaluation of ventricular blood removal as measured by head CT scanTime frame: Intra-procedure
  3. Comparison of patient outcome between groups at as measured by the Glasgow Coma Scale, extended Glasgow Outcome Scale, modified Rankin Scale.Time frame: 0-30 days post discharge from hospital

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Helsinki University

    Helsinki, Finland · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.